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Maresin1 (MaR1), a new anti-inﬂammatory and proresolving lipid mediator, has been proven to exert organ-protective eﬀects in
septic animal models. However, the potential mechanisms are still not fully elucidated. In this study, we sought to explore the
impact of MaR1 on metabolic dysfunction in cecal ligation and puncture- (CLP-) induced septic mice. We found that MaR1
signiﬁcantly increased the overall survival rate and attenuated lung and liver injuries in septic mice. In addition, MaR1 markedly
reduced the levels of proinﬂammatory cytokines (TNF-α and IL-6) and alleviated mitochondrial damage. Based on a 1H
NMR-based metabolomics analysis, CLP-induced septic mice had increased levels of acetate, pyruvate, and lactate in serum and
decreased levels of alanine, aspartate, glutamate, and fumarate in lungs. However, these metabolic disorders, mainly involving
energy and amino acid metabolism, can be recovered by MaR1 treatment. Therefore, our results suggest that the protective
eﬀects of MaR1 on sepsis could be related to the recovery of metabolic dysfunction and the alleviation of inﬂammation and
mitochondrial damage.
1. Introduction
Sepsis is a life-threatening clinical syndrome characterized
by multiple organ dysfunctions due to uncontrolled host
inﬂammatory responses towards infection or injury [1]. Sep-
sis is becoming a leading cause of morbidity and mortality
globally, because to date no eﬃcient antisepsis therapy is
available [2]. It is, therefore, important to discover speciﬁc
and eﬀective drugs to treat sepsis.
Maresin1 (MaR1), derived from docosahexaenoic acid
(DHA) by macrophages via 12-lipoxygenase [3], possesses
potent anti-inﬂammatory and proresolving properties
in vitro and vivo [4, 5]. A recent research showed that
MaR1 mitigated the lipopolysaccharide (LPS) level and
enhanced the bacteria clearance in septic mice [6]. Our previ-
ous study indicated that MaR1 improved alveolar ﬂuid
clearance via upregulation of epithelial sodium channel
expression in an LPS-induced acute lung injury model [7].
However, the potential mechanisms of MaR1 for sepsis treat-
ment are still far from being fully understood.
Metabolomics is an “omics” technique that attempts to
analyze all low-molecular-weight metabolites in biological
samples and explore metabolic mechanisms underlying dis-
ease development or drug treatment [8]. Metabolic alter-
ations can be revealed by metabolomic methods for early
diagnosis and prognosis in sepsis-induced acute lung injury
[9–11]. Moreover, NMR-based metabolomic results showed
that the levels of metabolites involved in energy metabolism
and inﬂammatory process were disrupted in the animal
model of sepsis [12, 13]. In our previous study, MaR1 signif-
icantly decreased the lactate level in CLP-induced septic mice
[14]. We also found that MaR1 reversed the mitochondrial
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dysfunction by upregulating expressions of the mitochon-
drial respiratory chain enzyme complexes COX I and COX
IV in murine sepsis [14], suggesting that MaR1 may inﬂu-
ence the metabolic responses, but the metabolic eﬀects of
MaR1 in sepsis need to be elucidated. In the present work,
we analyzed metabolic proﬁles of serum, lung, and liver
samples in CLP-induced sepsis mice after MaR1 treatment
and aimed to explore the MaR1-altered metabolic pathways
in sepsis.
2. Materials and Methods
2.1. Materials. Maresin1 (7,14-dihydroxydocosa-4Z,8Z,10,
12,16Z,19Z-hexaenoic acid, MaR1) was from Cayman
Chemical Company (Ann Arbor, MI, USA). The chemical
structure of MaR1 is shown in Figure 1(a). TNF-α and
IL-6 ELISA kits were from R&D Systems (Minneapolis,
MN, USA). Blood biochemistry assay kits (ALT/AST)
were from Jiancheng Bioengineering Institute (Nanjing,
Jiangsu, China).
2.2. Animals, Experimental Procedure, and Treatments.
Eight-week-old male C57B6/L mice weighing 20–25 g
(Shanghai Experimental Animal Centre, China) were housed
four per cage and maintained in a speciﬁc pathogen-free
room with controlled temperature (22–24°C) and humidity
(60–65%) under a 12 h light/dark cycle. The mice were given
standard laboratory chow and water ad libitum. Principles of
laboratory animal care were followed, and all procedures
were conducted according to the guidelines established by
the National Institutes of Health (NIH Publication No.
85-23, revised 1996), and every eﬀort was made to minimize
suﬀering. This study was approved by the Animal Care and
Use Committee of Wenzhou Medical University.
Mice were anesthetized with 2% sodium pentobarbi-
tal (80mg/kg, intraperitoneally) and randomly assigned to
three groups: sham group, CLP group, and CLP+MaR1
group (MaR1: 100ng/mice, intraperitoneally). Sepsis was
induced surgically by CLP as described previously [15].
Midline abdominal incision was made after the abdomen
was disinfected and the cecum was exposed. Then, the cecum
was ligated below the ileocecal valve and a through-and-
through puncture was performed with a 20-gauge needle
for mid-grade sepsis. Lastly, it was relocated into the abdom-
inal cavity without spreading faeces from the cecum onto the
abdominal wall wound margins. The sham mice underwent
the same procedure, but the cecum was neither ligated
nor punctured. MaR1 (100 ng/mice) was intraperitoneally
administered 1 h later after surgery. The experimental sched-
ule is shown in Figure 1(b).
2.3. Survival Analysis. The mice which had undergone CLP
surgery were randomly administered MaR1 (100 ng) or
saline in the sham group (intraperitoneal injection; n = 12
/per group). The survival rate of mice was monitored for 8
days after CLP surgery and recorded every day.
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Figure 1: MaR1 improved the survival rate of mice in cecal ligation and puncture- (CLP-) induced septic model (a); the chemical structure of
MaR1 (b); experimental schedule (c). MaR1 (100 ng/mice, i.p.) was administered to C57BL/6 mice 1 h after surgery, and an equal volume of
saline was given in both the sham and CLP groups. The survival rate was observed for 8 days. Survival of the two subgroups was estimated by
Kaplan–Meier survival curves; comparisons were performed by the log-rank test (n = 12), ∗P < 0 05.
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2.4. Pathological and Biological Studies. The lung and liver
samples were obtained immediately after exsanguination
(24 h after CLP) then embedded in paraﬃn and stained with
haematoxylin and eosin (H&E) for light microscope analysis.
Organ injury scores were performed by two independent
investigators blinded to the research assignment following
the applicable criteria [16]. Whole blood samples from mice
were obtained by cardiac puncture 24 h after CLP surgery
and then centrifuged at 3000 g for 10min to collect serum.
The serum levels of TNF–α, IL-6, alanine aminotransferase
(ALT), and aspartate aminotransferase (AST) were, respec-
tively, determined using ELISA kits according to the manu-
facturer’s protocols.
2.5. Transmission Electron Microscopy. For electron micros-
copy experiments, the lung tissues were harvested 24 h after
CLP and the eﬀect of MaR1 was assessed by transmission
electron microscopy analysis. Mice were euthanized and then
perfused with cold PBS, followed by 2% glutaraldehyde in
0.1M phosphate buﬀer (pH7.4), and processed for transmis-
sion electron microscopy (TEM), as described previously
[17]. Images were acquired digitally from a randomly
selected pool of 10 ﬁelds under each condition.
2.6. 1H NMR Sample Collection and Extraction. Lung and
liver samples were collected, frozen in liquid nitrogen rap-
idly, and stored at −80°C until use. The extraction was
performed as previously described [18]. Prior to NMR
analysis, the tissue sample was weighed into an Eppendorf
tube, mixed with ice-cold methanol (4mL/g) and distilled
water (0.85mL/g), and homogenized by a handheld homog-
enizer. Then, ice-cold chloroform (2mL/g) and distilled
water (2mL/g) were added into the mixture, vigorously
vortex-mixed for 10 s, and centrifuged at 1000 g for 15min
at 4°C. The supernatant was extracted carefully into a new
tube and lyophilized for 48 h. The dried extracts were resus-
pended in 500μL D2O containing sodium trimethylsilyl pro-
pionate-d4 (TSP, 0.25mM) and then transferred to a 5mm
NMR tube for NMR analysis. In addition, 200μL of serum
sample was thawed and diluted with 250μL of phosphate
buﬀer and 50μL of D2O. The diluted serum was mixed and
centrifuged at 12,000 g at 4°C for 15min. After that, 500μL
of supernatant was transferred into a NMR tube for analysis.
2.7. 1H NMR Spectrometry. The 1H NMR spectra were
measured by using a Bruker Avance III 600 spectrometer
equipped with a triple resonance probe (Bruker BioSpin,
Rheinstetten, Germany) at 128K. A standard single-pulse
sequence (ZGPR) with water signal presaturation was
employed to acquire NMR spectra of tissue extracts. For
serum sample, the Carr-Purcell-Meiboom-Gill (CPMG)
pulse sequence with a ﬁxed receiver-gain value was per-
formed in order to minimize broad NMR peaks from pro-
teins and lipids. The main acquisition parameters were set
as follows: spectral width = 12,000Hz, data points = 256 K,
relaxation delay = 4 s, and acquisition time = 2 66 s per scan.
The 1H NMR spectra were corrected manually for phase
and baseline using TopSpin 3.0 software (Bruker BioSpin,
Rheinstetten, Germany). The spectra of serum samples were
referenced to the methyl peak of lactate at 1.33 ppm, while
the spectra of tissue samples were referenced to the TSP peak
at 0 ppm. The “icoshift” procedure was used to align NMR
spectra in MATLAB software (R2012a, The MathWorks
Inc., Natick, MA, USA) [19]. The spectral regions from 0.5
to 10.0 ppm excluding the residual water signals (from 4.7
to 5.2 ppm) were subdivided and integrated to binning data
with a size of 0.01 ppm.
2.8. Multivariate and Statistical Analysis. In this study, all
mice were randomly assigned to experimental procedures
including housing and feeding, animal grouping, CLP sur-
gery, and MaR1 treatment. Principal component analysis
(PCA) was used to obtain an overview of the metabolic pat-
tern of animal models using the SIMCA software (v. 12.0,
Umetrics, Umeå, Sweden). Prior to PCA, NMR data were
Pareto-scaled for improving data comparability. All data
were analyzed by one-way analysis of variance (ANOVA)
followed by Fisher’s LSD test using SPSS software (version
13.0, SPSS). Survival of the two subgroups was estimated by
Kaplan–Meier survival curves and compared by the log-rank
test. In this study, a statistically signiﬁcant diﬀerence was
considered when P value <0.05. Heat map and metabolic
pathway analyses were conducted by using MetaboAnalyst
3.0 [20]. The result of pathway analysis was presented
according to P values from the pathway enrichment analysis
and pathway impact values from the pathway topology
analysis, and the metabolic pathway with high values of these
two parameters, namely, located in the top-right region, was
identiﬁed as the most important pathway.
3. Results
3.1. MaR1 Improved Survival Rate and Alleviated Lung and
Liver Injury in CLP-Induced Septic Mice. As shown in
Figure 1(c), MaR1 signiﬁcantly increased the survival rate
compared with the septic group (58.33% versus 16.67%;
P < 0 05). Pathologic examination revealed that mice in the
sham group displayed normal tissue histology (Figures 2(a)
and 2(d)). After CLP, the lung was characterized by neu-
trophil inﬁltration, haemorrhage, alveolar disarray, and
hyaline membrane (Figure 2(b)), while the liver showed
increased parenchymal inﬂammatory and degenerative
changes (Figure 2(e)). However, MaR1 administration obvi-
ously attenuated lung and liver injury (Figures 2(c) and
2(f)), which is further conﬁrmed by organ injury scores
(Figures 2(g) and 2(h)).
3.2. MaR1 Attenuated TNF-α, IL-6, and ALT/AST Levels in
CLP-Induced Septic Mice. To assess the eﬀect of MaR1 on
inﬂammatory response in CLP-induced septic mice, the con-
centrations of proinﬂammatory cytokines in serum were
detected at 24 h after CLP. The levels of TNF-α and IL-6 were
signiﬁcantly increased in serum of CLP-induced septic mice
compared with the sham group (Figures 3(a) and 3(b)).
However, after MaR1 treatment, TNF-α and IL-6 levels were
markedly reduced in serum of CLP-induced septic mice
(Figures 3(a) and 3(b)). In addition, we found that the levels
of ALT and AST were increased signiﬁcantly in CLP-induced
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septic mice as compared with the sham group (P < 0 01),
while their levels were notably downregulated after MaR1
treatment (Figures 3(c) and 3(d)).
3.3. MaR1 Mitigated Mitochondrial Damage in CLP-Induced
Septic Mice. As shown in Figures 4(a)–4(c), the mitochondria
in lung tissues from the CLP group were swollen with dis-
rupted or disintegrated cristae, and the osmiophilic lamellar
bodies had fused or disappeared. This mitochondrial damage
was mitigated in the CLP+MaR1 group.
3.4. MaR1 Aﬀected Metabolic Features of Serum and Lung
but Not Liver in CLP-Induced Septic Mice. Typical 1H NMR
spectra in serum, liver, and lung samples are illustrated in
Figures 5(a), 5(c), and 5(e). A series of metabolites were
identiﬁed, involving energy metabolisms (acetate, creatine,
glucose, lactate and pyruvate, and formate), lipid metabolism
(LDL/VLDL), amino acid metabolism (alanine, glutamine,
glycine, histidine, isoleucine, leucine, phenylalanine, tyro-
sine, and valine), and ketone bodymetabolism (acetone, acet-
oacetate, and 3-hydroxybutyrate).
In this study, PCA was applied to examine changes in
metabolic patterns among sham, CLP, and MaR1 groups.
PCA can clearly distinguish among these three groups based
on serum metabolome (Figure 5(b)). In addition, Figure 5(d)
indicates that lung metabolic patterns were also diﬀerent
among these three groups. For liver metabolome, the meta-
bolic pattern in the sham group was clearly separated from
the other two groups, while no obvious separation was
obtained between CLP and CLP+MaR1 groups (Figure 5(f)).
Furthermore, metabolites were quantiﬁed and illustrated
in a heat map (Figure 6). As can be seen from Figure 6(a),
the CLP+MaR1 group had higher levels of acetate, lactate,
fumarate, pyruvate, and tyrosine than the sham group, but
their levels were obviously reduced after MaR1 treatment.
Additionally, relative to the sham group, the levels of
LDL/VLDL, glucose, isoleucine, and acetone levels were
reduced in serum of CLP-induced septic mice. Of note,
MaR1 treatment markedly increased these metabolites in
serum (Figure 6(a)). However, there were no recovery trends
for other serum metabolites shown in Figure 6(a).
In the lung, we also identiﬁed several metabolites that
show a recovery trend after MaR1 treatment; for example,
acetate and isoleucine levels were apparently increased in
the CLP group relative to the sham group but decreased in
the CLP+MaR1 group (Figure 6(b)). A decrease in lung tau-
rine caused by CLP was recovered to the normal level after
MaR1 treatment. In addition, a slight recovery trend was also
found for glycine, alanine, glutamate, lactate, and aspartate in
lung, as shown in Figure 6(b).
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Figure 2: MaR1 attenuated lung and liver injury in CLP-induced septic mice. The lung and liver tissues were obtained immediately after
exsanguination (24 h after CLP), and the eﬀect of MaR1 was assessed histologically in H&E-stained sections (original magniﬁcation ×100).
Inset shows 40x magniﬁcation of the slides. (a-c) Lung tissues, (d-f) liver tissues, (g) lung injury scores (n = 5 per group), and (h) liver
injury scores (n = 5 per group). Data are presented as mean ± SD. ∗P < 0 05 and ∗∗P < 0 01, n = 5 per group.
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Most metabolites in the liver did not show a recovery
trend, but increased levels of valine and acetate in the CLP
group relative to the sham group were mildly reduced after
MaR1 administration (Figure 6(c)).
3.5. Metabolic Pathway Changes in CLP-Induced Septic Mice
after MaR1 Treatment. Furthermore, metabolic pathway
analysis was performed on the basis of metabolites that
show a recovery trend after MaR1 treatment. Figure 7(a)
illustrates an overview of pathway analysis using serum
metabolites according to P values from the pathway
enrichment analysis and pathway impact values from the
pathway topology analysis. Pyruvate metabolism was identi-
ﬁed as a key metabolic pathway aﬀected by MaR1 treatment
due to its relatively high pathway impact value and statisti-
cally signiﬁcance (Figure 7(a)). In the present study, we
detected three metabolites, pyruvate, acetate, and lactate, in
pyruvate metabolism via NMR-based metabolomics
(Figure 7(b)). Results show that CLP-induced septic mice had
higher levels of pyruvate (Figure 7(c)), acetate (Figure 7(d)),
and lactate (Figure 7(e)) in serum as compared with normal
control mice, but their levels were signiﬁcantly reduced after
MaR1 treatment.
In lung tissue, we identiﬁed alanine, aspartate, and gluta-
mate metabolism as a key metabolic pathway (Figures 8(a)
and 8(b)). Compared with the sham group, the levels of ala-
nine (Figure 8(c), P < 0 01), aspartate (Figure 8(d), P < 0 01),
glutamate (Figure 8(e), P < 0 001), and fumarate (Figure 8(f),
P > 0 05) were decreased in lung tissue of the CLP
group; however, their levels were marginally increased after
MaR1 treatment.
4. Discussion
Maresin1 (MaR1) is a new family of special proresolving
mediators (SPMs) that are derived from endogenous DHA.
SPMs have been shown to exert potent protective eﬀects in
humans’ biology and health [21, 22]. Our results show that
the treatment of MaR1 markedly increased the survival rate
and alleviated lung and liver injury in CLP-induced septic
mice. In addition, our data demonstrate that MaR1 treatment
signiﬁcantly reduced the levels of TNF-α and IL-6 in plasma,
which may inﬂuence the patients’ outcome in critical illness
[23]. Korner et al. reported that Omega-3 fatty acids reduced
inﬂammation and improved sepsis survival in mice by stim-
ulating the endogenous production of MaR1 [24]. Moreover,
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Figure 3: MaR1 reduced TNF-α, IL-6, and ALT/AST levels in CLP-induced septic mice. Blood samples were collected after CLP surgery at
24 h time point and then centrifuged at 3000 g for 10min to collect serum. (a, b) The serum levels of TNF–α and IL-6 were, respectively,
determined using ELISA kits. (c, d) Then, the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in blood
were determined by biochemistry assay kits. Data are presented as mean ± SD. ∗P < 0 05 and ∗∗P < 0 01, n = 5 per group.
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Figure 4: MaR1 mitigated mitochondrial damage in CLP-induced septic mice. For electron microscopy experiments, the lung tissues were
harvested 24 h after CLP and the eﬀect of MaR1 was assessed by transmission electron microscopy analysis (original magniﬁcation
×15,000). The mitochondrial ultrastructure changes in three experimental groups were indicated by the white arrows.
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the organ-protective eﬀect of MaR1 was also observed in
murine sepsis by several researchers [6, 14, 25].
Although MaR1 has demonstrated a potential protective
eﬀect on sepsis, its clinical application is still in its infancy
[21]. Exploring the metabolic mechanisms of MaR1 will
promote its clinical development. In our previous study,
for example, we used an NMR-based metabolomics anal-
ysis to examine the metabolic responses of the basic
ﬁbroblast growth factor in streptozotocin-induced diabetic
rats and provide several possible mechanisms of the
glucose/lipid-lowering eﬀect [18]. Herein, we investigated
metabolic changes in CLP-induced septic mice after MaR1
treatment using NMR-based metabolomics and found two
mainmetabolic pathways recovered byMaR1, including pyru-
vate metabolism and alanine, aspartate, and glutamate
metabolism.
4.1. MaR1 Recovered Pyruvate Metabolism in CLP-Induced
Septic Mice. Pyruvate metabolism has been closely associated
with human disease by maintaining energy metabolism
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Figure 5: 1H-NMR-based metabolic proﬁles patterns in septic mouse treatment with MaR1. Representative 1H NMR spectra of serum (a),
lung (c), and liver (e) samples obtained from the mice, respectively. The PCA score plot based on the 1H NMR spectra of serum (b), lung
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homeostasis [26]. Pyruvate is formed from glucose through
glycolysis and then oxidized to CO2 and H2O via the tricar-
boxylic acid (TCA) cycle or transformed to lactate by anaer-
obic glycolysis. In the present study, our results reveal that
MaR1 can eﬀectively recover abnormal increases in serum
pyruvate and lactate levels in CLP-induced septic mice, sug-
gesting a recovery of pyruvate metabolism after MaR1 treat-
ment. Of note, lactate is an established indicator in tissue
hypoxia and mitochondrial dysfunction in critical illness
[27, 28]. Recent ﬁndings in septic patients have reported an
association between increased serum lactate level with organ
dysfunction and outcomes [29, 30]. Our previous study also
found that MaR1 remarkably decreased the serum level of
lactate in septic mice [14]. Therefore, MaR1 may improve
lactate clearance in sepsis. Moreover, these ﬁndings sup-
ported MaR1-induced alleviation of the mitochondrial
damage from the metabolic perspective. Acetate, as a con-
tributor of the TCA cycle, is indirectly related to pyruvate
metabolism. Stringer et al. [11] detected a slight increase in
plasma acetate level in patients with sepsis-induced acute
lung injury relative to healthy controls. In our study, as com-
pared with normal control mice, serum acetate level was
signiﬁcantly increased in CLP-induced septic mice. Yet,
it should be noted that this increase was eﬀectively recov-
ered after MaR1 treatment. Bakalov et al. [31] reported
that a reduced acetate level may be a metabolic feature
in a Drosophila melanogaster model of surviving sepsis.
Taken together, the recovery of pyruvate metabolism
induced by MaR1 treatment could be contributed to its
potential therapeutic eﬀect in CLP-induced septic mice.
4.2. MaR1 Recovered Alanine, Aspartate, and Glutamate
Metabolism in CLP-Induced Septic Mice. Metabolomics
results also reveal that MaR1 treatment recovered abnor-
mal metabolism of alanine, aspartate, and glutamate in
CLP-induced septic mice. Glutamate plays a vital role in
the biosynthesis of proteins in living beings. The reduction
in glutamate level in plasma has been linked to poor out-
comes in septic shock patients [32]. In the present study,
we found that the glutamate level in the lung was signiﬁcantly
decreased in the CLP group. Reduced lung glutamate pro-
duction can result in a decrease in systemic glutamate avail-
ability in hyperdynamic sepsis [33]. Alteration in glutamate
metabolism may also inﬂuence Th17 cell diﬀerentiation by
aﬀecting methylation of Foxp3 in autoimmune disease [34].
MaR1 could augment the generation of Tregs and regulated
cytokine production from ILC2s in the allergic lung inﬂam-
matory model [35]. Thus, MaR1 signiﬁcantly increased the
level of glutamate in the lung, indicating that MaR1 may
aﬀect T cell responses via maintaining glutamate metabolism
homeostasis in sepsis. However, their causal relationships
need to be further explored.
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Figure 6: Heat map visualization of the identiﬁed diﬀerential metabolites in septic mouse treatment with MaR1. Heat maps of metabolites in
serum (a), lungs (b), and liver (c) of septic mouse treatment with MaR1.
7Mediators of Inﬂammation
Alanine has a close association with multiple metabolic
pathways such as glycolysis, gluconeogenesis, and the TCA
cycle. In this study, the alanine level in lung tissue was signif-
icantly reduced in CLP-induced septic mice as compared
with normal control mice. This ﬁnding may be due to a sig-
niﬁcant increase in ALT level in CLP-induced septic mice,
since ALT can catalyse the transfer of an amino group from
alanine to α-ketoglutarate and form pyruvate and glutamate.
However, Izquierdo-Garcia et al. [13] found an increased
level of alanine in lung tissue of septic rats induced by cecal
ligation and puncture. We speculate that this diﬀerence
could be attributed to diﬀerent sepsis modelling procedures.
Additionally, we found that MaR1 treatment slightly
increased the level of alanine in the lung of CLP-induced
septic mice.
Aspartate is synthesized from an intermediate of the TCA
cycle, oxaloacetate, by transamination. Our results show that
MaR1 treatment mildly recovered the CLP-induced reduc-
tion in lung aspartate level. The same trend was also obtained
in the level of lung fumarate, which is an important
intermediate of the TCA cycle. Therefore, MaR1 could main-
tain energy metabolism homeostasis in the lung of
CLP-induced septic mice. Consistent with this ﬁnding, we
also found that MaR1 ameliorated the CLP-induced ultra-
structural damage of mitochondria in lung tissue by trans-
mission electron microscopy analysis.
4.3. MaR1 Improved Taurine Level in Lung of CLP-Induced
Septic Mice. Oxidative stress has been implicated in the
pathogenesis of sepsis [36, 37]. Taurine can enhance the
ability of the antioxidant defence system by protecting anti-
oxidant enzymes [38]. In this study, a signiﬁcant decrease
in taurine level was detected in the lung of CLP-induced
septic mice as compared with normal control mice, sug-
gesting a damaged antioxidant defence system in septic
mice. However, of note, we found that MaR1 treatment
obviously increased the lung taurine level. The inhibitory
eﬀect of MaR1 on oxidative stress was also reported in
lung I/R injury and carbon tetrachloride-induced hepatic
injury [39, 40]. Thus, we speculate that the potential
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Figure 7: Metabolic pathway analysis in serum of septic mouse treatment with MaR1. Pathway analysis carried out by the pathway topology
analysis among three groups (a) and the pathway ﬂowchart of pyruvate metabolism (b). The key metabolites are shown in (c)~(e). ∗P < 0 05,
∗∗P < 0 01, and ∗∗∗P < 0 001, n = 6 per group.
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therapeutic eﬀect of MaR1 on CLP-induced sepsis may be
linked with the recovery of taurine-mediated defence against
oxidative stress.
5. Conclusions
The present study suggested that MaR1 treatment improved
the survival rate of CLP-induced septic mice in multiple
ways, including the recovery of lung and liver injuries, the
reduction of inﬂammatory cytokines, and the attenuation
of mitochondrial damage. Furthermore, using a metabolo-
mics analysis, we also found that MaR1 could alleviate
metabolic disorders in CLP-induced septic mice, mainly
involving pyruvate metabolism, alanine, aspartate, and gluta-
mate metabolism, as well as lung taurine level. Yet, it is worth
noting that MaR1 signiﬁcantly regulated the metabolic
changes in serum and lung but not liver in septic mice. The
potential explanation underlying this phenomenon could be
due to the time eﬀect of MaR1 treatment on sepsis. There-
fore, the impacts of MaR1 on hepatic metabolic response
might occur for an extended period. Our ﬁndings reveal a
novel metabolic mechanism for the anti-inﬂammatory and
proresolving actions of MaR1 in sepsis. MaR1 may provide
new opportunities to design “metabolic targeted” therapies
with high accuracy in treating sepsis. However, several limi-
tations or future works should be considered: on the one
hand, based on the present preliminary study, cause-eﬀect
associations among MaR1, metabolism, and sepsis cannot
be proved. Therefore, cellular experiments or other animal
models are recommended to discover more evidence on
the therapeutic mechanisms of MaR1 in sepsis. On the other
hand, metabolomics needs to be coupled with other omics
techniques (e.g., genomics and proteomics) for a better
understanding of the eﬀect of MaR1 on metabolic regulation
and sepsis treatment. We believe that a deeper insight into
the MaR1 therapeutic mechanisms will promote its clinical
development and application.
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